

magc 1642

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Rastelli, et al

EXAMINER: Rawlings Stephen L.

SERIAL NUMBER: 10/016,253

ART UNIT: 1642

FILING: DATE: December 10, 2001

FOR: METHOD OF DETECTING AND TREATING TUBEROUS SCLEROSIS
COMPLEX ASSOCIATED DISORDERS

Mail Stop IDS

Commissioner of Patents

P.O. Box 1450

Alexandria, VA 22313-1450

TRANSMITTAL LETTER

Transmitted herewith for filing in the present application are the following documents:


1. Supplemental Information Disclosure Statement (2 pages), in duplicate;
2. Modified Form 1449/PTO (2 pages) in duplicate;
3. No copies of Cited references and A1-A3 and
4. Copies of Cited references B3-B14 and C3-C7 and;
5. Return Postcard

No fee is believed to be due at this time. However, the Commissioner is authorized to charge any additional fees that may be due to Deposit Account No.502648, Reference No. Cura 342 (21402-042). A duplicate copy of this transmittal letter is enclosed.

If the enclosed papers are considered incomplete, the Mail Room and/or the Application Branch is respectfully requested to contact the undersigned at 203/974-6303, New Haven, Connecticut.

Date: March 15, 2004

Respectfully submitted,


George Yahwak, Reg. No. 26,824
c/o CuraGen Corporation
555 Long Wharf Drive
New Haven, CT 06511
Tel: (203) 974-6303
Fax: (203) 401-3351



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S): Rastelli, et al.

EXAMINER: Rawlings Stephen L.

SERIAL NUMBER: 10/016,253

ART UNIT: 1642

FILING DATE: December 10, 2001

FOR: METHOD OF DETECTING AND TREATING TUBEROUS SCLEROSIS
COMPLEX ASSOCIATED DISORDERS

Mail Stop IDS

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, Applicants hereby make of record the documents attached modified Form PTO-1449.

This Supplemental Information Disclosure Statement is being filed with in three months of the mailing date of the International Report of PCT/ US01/47839 . Accordingly, no fee or certification is believed required.

It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application.


By Submitting this Information Disclosure Statement, the Applicant makes no representation that: (1) a search has been performed, or that more relevant information

does not exist; and (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. § 1.56(b).

The order of presentation of the references should not be constructed as an indication of the importance of the references. The Examiner is urged to form his/her own conclusion regarding the relevance of the cited information.

Please charge any fees that may be due, as a result of this submission to Deposit Account No. 502648, Reference No. 21402-042(Cura 342).

Respectfully submitted,



Date: March 15, 2004

George Yahwak, Reg. No. 26,824
c/o CuraGen Corporation
555 Long Wharf Drive
New Haven, CT 06511
Tel: (203) 974-6303
Fax: (203) 401-3351

Please type a plus sign (+) in this box



PTO/SB (12-97)
Approved for use through 9/30/00. OMB 0651-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

Modified Form 1449/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	10/016253
	Filing Date	10-Dec-2001
	First Named Inventor	Rastelli, et al.
	Group Art Unit	1642
	Examiner Name	Rawlings Stephen L.
	Attorney Docket Number	21402-042 Cura 342

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A1	4,816,567	03/28/89	Genentech, Inc.	530	387	04/08/1983
	A2	5,225,539	07/06/93	Medical Research Council	530	387.3	10/25/1991
	A3	5,871,697	02/16/99	CuraGen Corporation	422	68.1	10/24/1995

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document Office	Number	Name of Patentee(s) or Applicant(s)	Date of Publication	Translation Yes	No
	B3	EP	125,023	Cabilly, et al.	11/14/1984	x	
	B4	EP	171,496	Taniguchi, et al.	02/19/1986	x	
	B5	EP	173,494	Morrison, et al.	03/05/1986	x	
	B6	EP	184,187	Kudo, et al.	06/11/1986	x	
	B7	WO	86/01533	Neuberger, et al.	03/13/1986	x	
	B8	WO	97/18454	Thompson Timothy	05/22/1997	x	
	B9	WO	00/61612	Wang, et al.	10/19/2000	x	
	B10	WO	02/08288	Baker, et al.	01/31/2002	x	
	B11	WO	02/47534	Wang, et al.	06/20/2002	x	
	B12	WO	02/62947	Pranela Rameshwar	02/15/2002	x	
	B13	WO	02/86122	Legrain, et al.	10/31/2002	x	
	B14	WO	02/86443	Aziz, et al.	10/31/2002	x	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.
	C3	Nucleotide Accession Number: AJ251685 (28-JAN-2003).
	C4	Hopp, T. P. and K. R. Woods (1981). "Prediction of protein antigenic determinants from amino acid sequences." Proc Natl Acad Sci U S A 78(6): 3824-8.
	C5	Kyte, J. and R. F. Doolittle (1982). "A simple method for displaying the hydropathic character of a protein." J Mol Biol 157(1): 105-32.
	C6	Liu, A. Y., R. R. Robinson, et al. (1987). "Chimeric mouse-human IgG1 antibody that can mediate lysis of cancer cells." Proc Natl Acad Sci U S A 84(10): 3439-43.
	C7	Shimkets, R. A., D. G. Lowe, et al. (1999). "Gene expression analysis by transcript profiling coupled to a gene database query." Nat Biotechnol 17(8): 798-803.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, Serial No. _____, filed _____, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered.

Include copy of this form with next communication to applicant.

